. 2022 Aug 24;23(17):9591. doi: 10.3390/ijms23179591

Table 1.

Demographic and clinical data.

Variable	Control (n = 45)	FE (n = 15)	ME (n = 40)	ME_R (n = 19)	ME_NR (n = 21)	ME_A (n = 16)	ME_T (n = 23)
Variable	Control (n = 45)	FE_1 (n = 11)	ME (n = 40)	ME_R (n = 19)	ME_NR (n = 21)	ME_A (n = 16)	ME_T (n = 23)
Sex (F/M)	20/25	4/11	13/27	5/14	8/13	4/12	9/14
Sex (F/M)	20/25	3/8	13/27	5/14	8/13	4/12	9/14
Age (years)	41.22 ± 10.58	31.73 ± 15.53	39.85 ± 11.26	40.00 ± 12.15	39.71 ± 10.69	37.69 ± 9.12	41.39 ± 12.73
Age (years)	41.22 ± 10.58	32.36 ± 16.24	39.85 ± 11.26	40.00 ± 12.15	39.71 ± 10.69	37.69 ± 9.12	41.39 ± 12.73
IGF-2 (ng/mL)	114.24 ± 55.00	66.93 ± 39.99	144.06 ± 30.84	148.64 ± 33.41	140.95 ± 28.64	144.68 ± 30.99	143.87 ± 31.93
IGF-2 (ng/mL)	114.24 ± 55.00	153.45 ± 30.98	144.06 ± 30.84	148.64 ± 33.41	140.95 ± 28.64	144.68 ± 30.99	143.87 ± 31.93
IGFBP-7 (ng/mL)	64.9174 ± 25.36	54.04 ± 23.49	78.28 ± 18.55	81.98 ± 15.61	74.93 ± 20.67	76.57 ± 21.90	79.09 ± 16.65
IGFBP-7 (ng/mL)	64.9174 ± 25.36	82.47 ± 27.04	78.28 ± 18.55	81.98 ± 15.61	74.93 ± 20.67	76.57 ± 21.90	79.09 ± 16.65
PANSS-P	-	21.27 ± 5.02	22.92 ± 8.12	22.21 ± 8.16	23.57 ± 8.22	22.25 ± 9.73	22.91 ± 6.81
PANSS-P	-	11.33 ± 4.06	22.92 ± 8.12	22.21 ± 8.16	23.57 ± 8.22	22.25 ± 9.73	22.91 ± 6.81
PANSS-N	-	24.93 ± 8.92	27.42 ± 8.65	26.79 ± 7.44	28.00 ± 9.76	24.81 ± 6.92	29.04 ± 9.55
PANSS-N	-	16.78 ± 7.33	27.42 ± 8.65	26.79 ± 7.44	28.00 ± 9.76	24.81 ± 6.92	29.04 ± 9.55
PANSS-G	-	35.93 ± 9.38	38.15 ± 8.13	38.37 ± 7.65	37.95 ± 8.73	37.69 ± 9.16	38.30 ± 7.69
PANSS-G	-	23.22 ± 5.99	38.15 ± 8.13	38.37 ± 7.65	37.95 ± 8.73	37.69 ± 9.16	38.30 ± 7.69
PANSS-T	-	82.13 ± 19.37	88.5 ± 21.45	87.37 ± 19.20	89.52 ± 23.73	84. 75 ± 23.38	90.26 ± 20.31
PANSS-T	-	51.33 ± 15.66	88.5 ± 21.45	87.37 ± 19.20	89.52 ± 23.73	84. 75 ± 23.38	90.26 ± 20.31
SAAS	108.17 ± 59.32	155.33 ± 60.54	198.55 ± 89.67	172.86 ± 94.93	181.50 ± 88.51	205.21 ± 85.42	196.48 ± 95.32
Glucose (mg/dL)	-	87.14 ± 22.68	85.57 ± 14.17	84.62 ± 14.14	86.64 ± 14.65	82.54 ± 7.98	88.56 ± 17.74
TC ¹ (mg/dL)	-	142.75 ± 24.82	185.41 ± 54.35	170.93 ± 56.67	201.00 ± 49.13	184.31 ± 51.06	191.23 ± 58.67
TG ² (mg/dL)	-	77.75 ± 31.64	116.11 ± 60.04	103.57 ± 49.04	129.61 ± 69.45	117.77 ± 62.18	118.62 ± 60.74
Albumin (g/dL)	-	4.1225 ± 0.26	4.1223 ± 0.44	4.22 ± 0.40	4.01 ± 0.48	4.04 ± 0.41	4.22 ± 0.47

The mean values and the standard deviation of the different variables considered are shown. FE: First Episode drug-naïve patients, FE_1: First Episode group after treatment, ME: multiple or chronic patients, ME_R: ME patients who had previously responded to treatment, ME_NR: ME patients who had previously not responded to treatment, ME_A: ME who had abandoned treatment at least 1 month before the last psychotic episode took place and ME_T: ME who had been following treatment until the last psychotic episode took place. Sample size (N) is indicated for each column. ¹ TC: total cholesterol, ² TG: total triglycerides.